oral semaglutide approval Clinical Capsules: Becomes the First GLP-1 Approved for Weight Loss FDA Approves First ORAL GLP-1

GLP-1 receptor agonists slow gastric emptying but do not directly interact with reproductive hormones like oestrogen or progesterone Semaglutide (Wegovy) and liraglutide (Saxenda) do not require routine additional contraceptive precautions based on current evidence Tirzepatide reduces oral contraceptive exposure and requires barrier methods or non-oral contraception for 4 weeks after starting and after each dose increase Long-acting reversible contraceptives (IUDs, implants) are unaffected by gastric emptying and provide highly reliable alternatives during weight loss treatment Gastrointestinal side effects such as vomiting within 3 hours of taking oral contraceptives may compromise absorption and require missed pill guidance Weight loss medications should be discontinued before planned conception (typically 12 months depending on the specific agent) Table of Contents How Weight Loss Injections Work in Your Body Weight loss injections prescribed in the UK typically contain glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide (Wegovy) or liraglutide (Saxenda), or dual GIP/GLP-1 receptor agonists like tirzepatide

How was it stored

Managing your health can feel like navigating a maze with conditions like hypothyroidism

What causes nausea with semaglutide

Always consult your healthcare provider for proper advice